Take a look at our previous reports:

Our Ambition

Informed by the results of our materiality assessment, in 2023, we worked on identifying KPIs and defining targets to reach our 2028 call for action, as depicted in the graph below.

Our commitment to our call for action by 2028 remains unchanged, and we are reviewing the underlying targets and action plans to reflect the impact of the Jyseleca® transfer transaction that was completed at the end of January 2024.

The updated targets will provide the basis for our sustainability reporting as of 2024.

Our call for action by 2028

Our call to action 2028 (graphic)
Jyseleca®
Jyseleca® is the brand name for filgotinib